within Pharmacolibrary.Drugs.ATC.D;

model D08AJ01
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D08AJ01</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Benzalkonium is a quaternary ammonium compound often used as a topical antiseptic and disinfectant. It is primarily utilized for skin and mucous membrane disinfection, as well as a preservative in pharmaceutical and cosmetic products. Benzalkonium compounds are not systemically used as pharmaceuticals because of their local toxicity and strong irritating effects. The drug does not have approval for systemic administration.</p><h4>Pharmacokinetics</h4><p>No published clinical pharmacokinetic (PK) data for systemic absorption of benzalkonium in humans exists, as the compound is intended strictly for topical and local use and is not administered systemically.</p><h4>References</h4><ol><li><p>Zhou, T, et al., &amp; Zhang, J (2020). A Comparative Ocular Pharmacokinetics Study of Preservative-Free Latanoprost Unit-Dose Eye Drops and a Benzalkonium Chloride-Preserved Branded Product Following Topical Application to Rabbits. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 36(7) 522–528. DOI:<a href=\"https://doi.org/10.1089/jop.2019.0102\">10.1089/jop.2019.0102</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32310714/\">https://pubmed.ncbi.nlm.nih.gov/32310714</a></p></li><li><p>Rasmussen, CA, et al., &amp; Kiland, JA (2014). Benzalkonium chloride and glaucoma. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 30(2-3) 163–169. DOI:<a href=\"https://doi.org/10.1089/jop.2013.0174\">10.1089/jop.2013.0174</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24205938/\">https://pubmed.ncbi.nlm.nih.gov/24205938</a></p></li><li><p>de Jong, C, et al., &amp; van Best, J (1994). Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. <i>Graefe&#x27;s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie</i> 232(4) 221–224. DOI:<a href=\"https://doi.org/10.1007/BF00184009\">10.1007/BF00184009</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8034210/\">https://pubmed.ncbi.nlm.nih.gov/8034210</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D08AJ01;
